Form 4: Theravance Biopharma CEO Acquires Shares Under Equity Incentive Plan

Theravance Biopharma's CEO, Rick E. Winningham, acquired 2,068 ordinary shares at $9.85 per share under the company's equity incentive plan.

Summary

• Rick E. Winningham, CEO of Theravance Biopharma, acquired 2,068 ordinary shares on May 15, 2024.
• The shares were acquired at a price of $9.85 per share.
• The acquisition was made under the Issuer's Amended and Restated 2013 Equity Incentive Plan.
• Following the transaction, Winningham directly owns 1,852,641 ordinary shares.
• Winningham also indirectly owns 3,900 shares as custodian and 92,567 shares by trust.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the CEO's share acquisition signals confidence in the company, but it's a routine transaction under an existing plan.

Positives

• The CEO's share acquisition reflects confidence in the company's future prospects.
• The acquisition was part of the company's equity incentive plan, aligning management's interests with shareholders.

Industry Context

Share acquisitions by company executives are common and can be seen as a positive signal to the market, indicating confidence in the company's performance and future prospects. Equity incentive plans are a standard tool for aligning management and shareholder interests in the biopharmaceutical industry.

Comparison to Industry Standards

• Executive compensation packages in the biopharmaceutical industry often include equity grants and stock options to incentivize performance and align executive interests with shareholder value.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize equity incentive plans for their executives.

Related Party Transactions

• The share acquisition from the Issuer pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan is a related party transaction.

Stakeholder Impact

• The CEO's share acquisition could positively influence shareholder sentiment.

Key Dates